【レポートの概要（一部）】
1. Analyst View
2. Research Methodology
3. Global Cancer Drugs Market Outlook 2018
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. Global Cancer Generics Market Analysis 2018
5. Cancer Generic Drugs Industry
5.1 Oral Generic Drugs
5.1.1 Arimidex (Anastrozole)
5.1.2 Femara (Letrozole)
5.1.3 Hycamtin (Topotecan)
5.1.4 Stivarga (Regorafenib)
5.1.5 Tarceva (Erlotinib)
5.1.6 Xalkori (Crizotinib)
5.1.7 Xeloda (Capecitabine)
5.2 Generic Injectables
5.2.1 Camptosar (Irinotecan Hydrochloride)
5.2.2 Eloxatin (Oxaliplatin)
5.2.3 Gemzar (Gemcitabine Hydrochloride)
5.2.4 Navelbine (Vinorelbine Tartrate)
5.2.5 Platinol (Cisplatin)
5.2.6 Taxol (Paclitaxel)
5.2.7 Taxotere (Docetaxel)
6. Cancer Generics Market: Major Indications
6.1 Lung Cancer
6.1.1 Incidence Outlook
6.1.2 Commercialized Drugs
6.2 Breast Cancer
6.2.1 Incidence Outlook
6.2.2 Commercialized Drugs
6.3 Colorectal Cancer
6.3.1 Incidence Outlook
6.3.2 Commercialized Drugs
6.4 Stomach Cancer
6.4.1 Incidence Outlook
6.4.2 Commercialized Drugs
6.5 Prostate Cancer
6.5.1 Incidence Outlook
6.5.2 Commercialized Drugs
7. Market Dynamics
7.1 Indian Generic Cancer Drug Introduced in the US Market
7.2 Launch of Generic Drugs for Oncology
7.3 Increasing Cancer Burden Paving Way for Generics
7.4 Patent Expiry of Blockbuster Oncology Drugs
7.5 Strategic Collaborations
8. Key Players
8.1 Fresenius Kabi AG
8.1.1 Business Overview
8.1.2 Key Financials
8.1.3 Strategic Developments
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Key Financials
8.2.3 Strategic Developments
8.3 Hospira
8.3.1 Business Overview
8.3.2 Key Financials
8.3.3 Strategic Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Business Overview
8.4.2 Key Financials
8.4.3 Strategic Developments
8.5 Mylan
8.5.1 Business Overview
8.5.2 Key Financials
8.5.3 Strategic Developments
8.6 Sun Pharmaceuticals
8.6.1 Business Overview
8.6.2 Key Financials
8.6.3 Strategic Developments
List of Figures:
Figure 3-1: Global – Number of New Cancer Cases (Million), 2012 & 2025
Figure 3-2: Global – Cancer Incidences by Gender (Million), 2012
Figure 3-3: Global – Cancer Drugs Market (Billion US$), 2008-2013
Figure 3-4: Global – Cancer Drugs Market (Billion US$), 2014-2018
Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
Figure 3-7: Global – Cancer Treatment Modalities Revenue Share (%), 2013
Figure 4-1: Global – Cancer Generics Market (Billion US$), 2013-2018
Figure 6-1: Global – Number of New Lung Cancer Cases (Million), 2012 & 2020
Figure 6-2: Global – Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-3: Global – Number of New Breast Cancer Cases (Million), 2012 & 2020
Figure 6-4: Global – Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-5: Global – Number of New Colorectal Cancer Cases (Million), 2012 & 2020
Figure 6-6: Global – Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-7: Global – Number of New Stomach Cancer Cases (Million), 2012 & 2020
Figure 6-8: Global – Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-9: Global – Number of New Prostate Cancer Cases (Million), 2012 & 2020
Figure 6-10: Global – Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 8-1: Fresenius Kabi – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-2: Fresenius Kabi – Revenue Share by Region (%), 2013
Figure 8-3: Fresenius Kabi – Revenue Share by Business Segment (%), 2013
Figure 8-4: Actavis – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-5: Actavis – Revenue Share by Region (%), 2013
Figure 8-6: Actavis – Revenue Share by Business Segment (%), 2013
Figure 8-7: Hospira – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-8: Hospira – Revenue Share by Region (%), 2013
Figure 8-9: Hospira – Revenue Share by Business Segment (%), 2013
Figure 8-10: Teva – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-11: Teva – Revenue Share by Region (%), 2013
Figure 8-12: Hospira – Revenue Share by Business Segment (%), 2013
Figure 8-13: Mylan – Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-14: Mylan – Revenue Share by Region (%), 2013
Figure 8-15: Mylan – Revenue Share by Business Segment (%), 2013
Figure 8-16: Sun Pharma – Sales & Net Income (Billion US$), 2012-13/ 2013-14
Figure 8-17: Sun Pharma – Revenue Share by Business Segment (%), 2013-14
List of Tables:
Table 3-1: Most Prevalent Types of Cancer
Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates
Table 5-1: List of Companies Dealing in Generic Arimidex
Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 5-3: List of Companies Dealing in Generic Femara
Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 5-5: List of Companies Dealing in Generic Hycamtin
Table 5-6: List of Companies Dealing in Generic Xeloda
Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 5-8: List of Companies Dealing in Generic Camptosar
Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)
Table 6-2: Global – Key Lung Cancer Drugs and Patent Expiry Status
Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)
Table 6-4: Global – Key Breast Cancer Drugs and Patent Expiry Status
Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)
Table 6-6: Global – Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)
Table 6-8: Global – Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)
Table 6-10: Global – Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: Global – Key Cancer Drugs and Patent Expiry Status
Table 8-1: Fresnius Kabi Pharmaceuticals – Key Cancer Generic Drugs
Table 8-2: Actavis – Key Cancer Generic Drugs
Table 8-3: Hospira – Key Cancer Generic Products
Table 8-4: Teva Pharmaceuticals – Key Cancer Generic Drugs
Table 8-5: Mylan – Key Cancer Generic Drugs
Table 8-6: Sun Pharmaceuticals – Key Cancer Generic Drugs
【レポート販売概要】
■ タイトル：世界の癌治療用ジェネリック医薬品市場■ 英文：Global Cancer Generics Market Outlook 2018
■ 発行日：2014年8月
■ 調査会社：RNCOS
■ 商品コード：RNCS4087
■ 調査対象地域：グローバル
- イスラム旅行の世界市場About Islamic Travel Tourism is an elaborate concept that houses an array of considerations with respect to the needs and benefits of the tourists. Every individual tourist visits a particular destination with a destined objective and purpose. Consumers have a level of expectation, desire, and focus while traveling to a particular place and this aspect varies from each individual tourist to other. …
- 2014年ヨーロッパの分子血液型・分類検査および感染症NAT（核酸増幅検査）市場Complete report $19,700. DataPack (test volumes, sales forecasts, supplier shares) $12,800. This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the European molecular blood banking market during the next five years, and assist industry executives in developing effective business, new produc …
- GLYX-13 (大うつ病性障害)：医薬品市場予測及び分析（～2023）GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for …
- 非結晶性ポリエチレンテレフタラートの世界市場予測（～2022年）“The amorphous polyethylene terephthalate (APET) market is estimated to be USD 28.86 billion in 2017 and is projected to reach USD 40.85 billion by 2022, at a CAGR of 7.2% during the forecast period from 2017 to 2022.” The amorphous polyethylene terephthalate (APET) market is estimated to be USD 28.86 billion in 2017 and is projected to reach USD 40.85 billion by 2022, at a CAGR of 7.2% during the …
- 石油・ガス業界のM&A及び投資動向（四半期別）：Q1 2013Oil & Gas Quarterly Deals Analysis: M&A and Investment Trends – Q1 2013 Summary GlobalData's “Oil & Gas Quarterly Deals Analysis: M&A and Investment Trends – Q1 2013” report is an essential source of data and trend analysis on mergers and acquisitions (M&As) and financings in the oil and gas industry. The report provides detailed information on M&As, equity/debt offerings, private equity (PE), ven …
- 敗血症（セプシス）の疫学的予測EpiCast Report: Sepsis - Epidemiology Forecast to 2023 Summary Sepsis is a life-threatening complication arising from an infection; it occurs when the body’s response to the infection damages its own tissues and organs. Anyone can develop sepsis; however, the condition is more common among children
- Rosetta Resources Inc.：石油・ガスの開発・生産動向及びコスト分析– Q4, 2012Rosetta Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2012 Summary Rosetta Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- ヒトパピローマウイルス予防ワクチン：グローバル医薬品市場予測及び分析（～2022）PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022 Summary The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initia …
- CBRN（化学、生物、放射性物質、核兵器）セキュリティの世界市場About CBRND Chemical, biological, radiological, and nuclear (CBRN) security comprises of protective and preventive measures to combat situations that involve such perilous agents. CBRN security is a growing market, owing to the concerns regarding the protection of civilian lives and maintenance of economic stability. One of the primary reasons for the continuous demand for CBRN protection, detecti …
- エポキシ複合材料の世界市場予測（～2021）The epoxy composite market is projected to reach USD 33.06 Billion by 2021, at a CAGR of 7.34% from 2016 and 2021. Epoxy composites offer excellent compression and tensile strength, excellent modulus of elasticity, and high corrosion resistance. The increase in the penetration of advanced materials such as epoxy composite in various industries, such as wind energy, aerospace & defense, automotive …
- 医薬品安全性監視及び薬物安全性ソフトウェアの世界市場The global pharmacovigilance and drug safety software market is expected to grow at a CAGR of 6.5% from 2014 to 2019. North America region held the largest share of the pharmacovigilance and drug safety software market in 2014. However, Asian and Latin American countries symbolize high growth markets. This is owing to a rise in research outsourcing by pharmaceutical giants and growing public and p …
- 世界の新生児マススクリーニング検査市場（～2019）The global newborn screening market is categorized on the basis of test type, technology, product, and geography. The mass spectrometry market is expected to register the highest growth rate in the newborn screening market by technology, during the forecast period. This high growth is attributed to various nations opting for expanded newborn screening. Tandem mass spectrometry is a fundamental ins …
- 自動車RCTAS（リア・クロス・トラフィック・アラート・システム）の世界市場2016-2020About RCTAS The RCTAS is an extension of blind spot detection (BSD) systems, which is a type of collision avoidance system. Hence, the evolution of this system can be linked to that of BSD systems. The primary functional features of both systems are similar, except that the BSD is used for monitoring front sides of the vehicle; whereas, the RCTAS is developed for rear sides of the vehicle. BSD is …
- 世界の電動ショベル市場2015The Global Electric Shovel Industry Report 2015 is a professional and in-depth study on the current state of the Electric Shovel industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Electric Shovel market analysis is provided for the international markets including development trends, competitive landsc …
- 旅行代理店の世界市場：パッケージツアー、航空券予約、ホテル予約、クルーズ予約、列車予約、レンタカーサービス等About Travel Agencies Travel agencies are intermediary privately or publicly held organizations that extend travel and tourism-related services, acting as a front for tour operators and suppliers such as hotels, airlines, cruise lines, and tour package providers. In the process, the suppliers part with a portion of their earnings, which is considered commission for the agencies. They cater to the …
